Spots Global Cancer Trial Database for anaplastic thyroid cancer
Every month we try and update this database with for anaplastic thyroid cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer | NCT01701349 | Anaplastic Thyr... | Fosbretabulin +... Placebo + pacli... | 18 Years - | Mateon Therapeutics | |
| NGR-TNF in Treating Patients With Advanced Solid Tumors | NCT00098943 | Colorectal Canc... Head and Neck C... Kidney Cancer Unspecified Adu... | CNGRC peptide-T... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences | NCT05819593 | Anaplastic Thyr... | 18 Years - | Power Life Sciences Inc. | ||
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer | NCT00507429 | Anaplastic Thyr... | CA4P paclitaxel carboplatin | 18 Years - | Mateon Therapeutics | |
| Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy | NCT00095836 | Head and Neck C... | Gefitinib | 18 Years - | Massachusetts General Hospital | |
| Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3 | NCT03488134 | Thyroid Cancer | 20 Years - 80 Years | National Taiwan University Hospital | ||
| interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT) | NCT01774279 | Anaplastic Thyr... | Tissue, blood a... | 18 Years - 100 Years | Velindre NHS Trust | |
| Sacituzumab govitEcan in THYroid Cancers | NCT06235216 | Differentiated ... Anaplastic Thyr... | Sacituzumab gov... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Iodine I 131 in Treating Patients With Thyroid Cancer | NCT00416949 | Head and Neck C... | Patient-specifi... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases | NCT00062348 | Colorectal Canc... Head and Neck C... Metastatic Canc... | boronophenylala... sodium borocapt... conventional su... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients | NCT02862470 | Thyroid Cancer | 20 Years - | National Taiwan University Hospital | ||
| Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | NCT00126568 | Anaplastic Thyr... Recurrent Thyro... | sorafenib tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study | NCT04400474 | Neuroendocrine ... Anaplastic Thyr... Adenocarcinoma Pheochromocytom... Paraganglioma | Cabozantinib 40... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors | NCT00002608 | Adrenocortical ... Brain and Centr... Head and Neck C... Liver Cancer Malignant Mesot... Pheochromocytom... Sarcoma | cisplatin doxorubicin hyd... tamoxifen citra... conventional su... radiation thera... | - 65 Years | National Cancer Institute (NCI) | |
| Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma | NCT00115739 | Thyroid Cancer | Imatinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer | NCT02152137 | Anaplastic Thyr... Recurrent Thyro... | efatutazone paclitaxel | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer | NCT01701349 | Anaplastic Thyr... | Fosbretabulin +... Placebo + pacli... | 18 Years - | Mateon Therapeutics | |
| Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences | NCT05819593 | Anaplastic Thyr... | 18 Years - | Power Life Sciences Inc. | ||
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer | NCT00507429 | Anaplastic Thyr... | CA4P paclitaxel carboplatin | 18 Years - | Mateon Therapeutics | |
| Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | NCT05696548 | Anaplastic Thyr... | Lenvatinib Nivolumab | 20 Years - | National Cancer Center Hospital East | |
| A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | NCT00603941 | Anaplastic Thyr... | CS-7017 Paclitaxel | 18 Years - | Daiichi Sankyo | |
| Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | NCT04552769 | Thyroid Cancer Anaplastic Thyr... Undifferentiate... | Abemaciclib | 18 Years - | Stanford University | |
| Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | NCT05696548 | Anaplastic Thyr... | Lenvatinib Nivolumab | 20 Years - | National Cancer Center Hospital East | |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | NCT00068497 | Anaplastic Thyr... Insular Thyroid... Metastatic Para... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Parat... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Stage III Folli... Stage III Papil... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Verru... Stage IIIB Non-... Stage IV Lympho... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Esthe... Stage IVA Folli... Stage IVA Inver... Stage IVA Lymph... Stage IVA Midli... Stage IVA Mucoe... Stage IVA Papil... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Esthe... Stage IVB Folli... Stage IVB Inver... Stage IVB Lymph... Stage IVB Midli... Stage IVB Mucoe... Stage IVB Papil... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Esthe... Stage IVC Folli... Stage IVC Inver... Stage IVC Lymph... Stage IVC Midli... Stage IVC Mucoe... Stage IVC Papil... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Thryoid Gland N... Thyroid Gland M... Tongue Cancer Untreated Metas... | gefitinib | - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors | NCT00019331 | Colorectal Canc... Endometrial Can... Head and Neck C... Liver Cancer Lung Cancer Melanoma (Skin) Pancreatic Canc... Testicular Germ... Unspecified Adu... | aldesleukin ras peptide can... sargramostim DetoxPC | 18 Years - | National Cancer Institute (NCI) | |
| Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer | NCT06374602 | Anaplastic Thyr... | Pembrolizumab +... | 18 Years - | Saint Petersburg State University, Russia | |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | NCT00095693 | Anaplastic Thyr... Insular Thyroid... Recurrent Thyro... Stage III Folli... Stage III Papil... Stage IV Follic... Stage IV Papill... | sorafenib tosyl... laboratory biom... pharmacological... fludeoxyglucose... positron emissi... dynamic contras... | 18 Years - | National Cancer Institute (NCI) | |
| Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer | NCT01118065 | Head and Neck C... | everolimus | 18 Years - | National Cancer Institute (NCI) | |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | NCT02244463 | Anaplastic Thyr... Thyroid Cancer Differentiated ... | MLN0128 | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer | NCT00507429 | Anaplastic Thyr... | CA4P paclitaxel carboplatin | 18 Years - | Mateon Therapeutics | |
| Sacituzumab govitEcan in THYroid Cancers | NCT06235216 | Differentiated ... Anaplastic Thyr... | Sacituzumab gov... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| NGR-TNF in Treating Patients With Advanced Solid Tumors | NCT00098943 | Colorectal Canc... Head and Neck C... Kidney Cancer Unspecified Adu... | CNGRC peptide-T... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Iodine I 131 in Treating Patients With Thyroid Cancer | NCT00416949 | Head and Neck C... | Patient-specifi... | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | NCT02688608 | Anaplastic Thyr... | Pembrolizumab | 18 Years - | Stanford University | |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | NCT04579757 | Metastatic Soli... Colorectal Canc... Neuroendocrine ... Small Cell Lung... Gastric Cancer Soft Tissue Sar... Anaplastic Thyr... | Surufatinib and... Surufatinib and... | 18 Years - | Hutchmed | |
| Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma | NCT00115739 | Thyroid Cancer | Imatinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer | NCT00077103 | Head and Neck C... | filgrastim pegfilgrastim cisplatin doxorubicin hyd... fosbretabulin d... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| Review of Multimodality Management of Anaplastic Thyroid Cancer | NCT00280852 | Anaplastic Thyr... | - | AHS Cancer Control Alberta | ||
| Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy | NCT00095836 | Head and Neck C... | Gefitinib | 18 Years - | Massachusetts General Hospital | |
| Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | NCT00095693 | Anaplastic Thyr... Insular Thyroid... Recurrent Thyro... Stage III Folli... Stage III Papil... Stage IV Follic... Stage IV Papill... | sorafenib tosyl... laboratory biom... pharmacological... fludeoxyglucose... positron emissi... dynamic contras... | 18 Years - | National Cancer Institute (NCI) | |
| Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer | NCT00077103 | Head and Neck C... | filgrastim pegfilgrastim cisplatin doxorubicin hyd... fosbretabulin d... radiation thera... | 18 Years - | Case Comprehensive Cancer Center | |
| European Multicenter Study on Surgical Management of Advanced Thyroid Cancer | NCT05796960 | Thyroid Carcino... Thyroid Cancer Thyroid Neoplas... Thyroid Cancer,... Thyroid Cancer,... Thyroid Medulla... Anaplastic Thyr... | Thyroidectomy w... | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | NCT02012231 | Melanoma Thyroid Cancer Colorectal Canc... Non-small Cell ... Cholangiocarcin... Histiocytosis Hairy Cell Leuk... | PLX8394 | 18 Years - | Fore Biotherapeutics | |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | NCT02244463 | Anaplastic Thyr... Thyroid Cancer Differentiated ... | MLN0128 | 18 Years - | Dana-Farber Cancer Institute | |
| SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck | NCT00005647 | Head and Neck C... | paclitaxel semaxanib | 18 Years - | Case Comprehensive Cancer Center | |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | NCT00068497 | Anaplastic Thyr... Insular Thyroid... Metastatic Para... Recurrent Adeno... Recurrent Basal... Recurrent Esthe... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Parat... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Thyro... Recurrent Verru... Stage III Folli... Stage III Papil... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Verru... Stage IIIB Non-... Stage IV Lympho... Stage IV Non-sm... Stage IV Squamo... Stage IV Squamo... Stage IVA Adeno... Stage IVA Basal... Stage IVA Esthe... Stage IVA Folli... Stage IVA Inver... Stage IVA Lymph... Stage IVA Midli... Stage IVA Mucoe... Stage IVA Papil... Stage IVA Saliv... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVA Verru... Stage IVB Adeno... Stage IVB Basal... Stage IVB Esthe... Stage IVB Folli... Stage IVB Inver... Stage IVB Lymph... Stage IVB Midli... Stage IVB Mucoe... Stage IVB Papil... Stage IVB Saliv... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Stage IVB Verru... Stage IVC Adeno... Stage IVC Basal... Stage IVC Esthe... Stage IVC Folli... Stage IVC Inver... Stage IVC Lymph... Stage IVC Midli... Stage IVC Mucoe... Stage IVC Papil... Stage IVC Saliv... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Squam... Stage IVC Verru... Stage IVC Verru... Thryoid Gland N... Thyroid Gland M... Tongue Cancer Untreated Metas... | gefitinib | - | National Cancer Institute (NCI) | |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer | NCT00004089 | Head and Neck C... | filgrastim fluorouracil hydroxyurea paclitaxel conventional su... radiation thera... | 15 Years - 80 Years | National Cancer Institute (NCI) | |
| The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | NCT05102292 | Anaplastic Thyr... ATC | HLX208 | 18 Years - | Shanghai Henlius Biotech | |
| Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | NCT04552769 | Thyroid Cancer Anaplastic Thyr... Undifferentiate... | Abemaciclib | 18 Years - | Stanford University | |
| Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | NCT06362694 | Anaplastic Thyr... | Dabrafenib + Tr... | 18 Years - | Saint Petersburg State University, Russia | |
| Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer | NCT03565536 | Thyroid Cancer,... | Nexavar operation External radiat... | 18 Years - | Fujian Medical University | |
| interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT) | NCT01774279 | Anaplastic Thyr... | Tissue, blood a... | 18 Years - 100 Years | Velindre NHS Trust | |
| Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | NCT03085056 | Anaplastic Thyr... | Trametinib Paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma | NCT00115739 | Thyroid Cancer | Imatinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer | NCT00804830 | Thyroid Neoplas... Carcinoma Thyroid Cancer Metastatic Canc... | Bevacizumab | - | Region Skane | |
| Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer | NCT02726503 | Anaplastic Thyr... | Lenvatinib | 20 Years - | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer | NCT02726503 | Anaplastic Thyr... | Lenvatinib | 20 Years - | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer | NCT01164176 | Head and Neck C... | everolimus laboratory biom... | 18 Years - | Yonsei University | |
| Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer | NCT03565536 | Thyroid Cancer,... | Nexavar operation External radiat... | 18 Years - | Fujian Medical University | |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | NCT04579757 | Metastatic Soli... Colorectal Canc... Neuroendocrine ... Small Cell Lung... Gastric Cancer Soft Tissue Sar... Anaplastic Thyr... | Surufatinib and... Surufatinib and... | 18 Years - | Hutchmed | |
| The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation | NCT05102292 | Anaplastic Thyr... ATC | HLX208 | 18 Years - | Shanghai Henlius Biotech |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
